Pharma, Biotech and Generics Industry News | The Pharmaletter
WEBGenerics. 9 September 2024 A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 5 September 2024 Amid an explosion in investment and development milestones seen over the past decade ...
Pharmaceutical Industry News | The Pharmaletter
WEBAug 20, 2024 · MHRA finds no evidence to support a link between GLP-1s and suicidal thoughts. MHRA has concluded that the available evidence does not establish a causal relationship between glucagon-like peptide-1 (GLP-1) receptor agonists and suicidal behavior, suicidal ideation, self-injury and depression. 4 September 2024. 12 …
Pfizer acquires privately-held Bioren - Pharmaceutical industry …
WEB21 August 2005. Continuing its acquisition trail, pharmaceutical leviathan Pfizer has completed the purchase of the privately-held, California, USA-based firm Bioren, which specializes in technology for the optimization of antibodies that assist drugmakers in developing medicines with improved properties. Financial terms were not disclosed.
CROs keep growing, as Tigermed acquires Tokyo firm
WEBJul 31, 2024 · This article is accessible to registered users, to continue reading please register for free.. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the …
Pharma and Biotech News | The Pharmaletter
WEB2 days ago · Research shows migraine market to reach $16.4 billion by 2033. The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024. Biotechnology.
About The Pharma Letter | The Pharmaletter
WEB3 days ago · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
UB start-up Abceutics acquired by Merck | The Pharmaletter
WEBApr 8, 2024 · Merck acquired Abceutics for a potential consideration of up to $208 million, including contingent milestone payments based upon the progress of candidates under the agreement. Dr Balthasar, the David and Jane Chu Endowed Chair in Drug Discovery and Development in the Department of Pharmaceutical Sciences, launched the start-up in 2020.
Vilya Therapeutics | Biotechnology - The Pharmaletter
WEBA computational biotechnology company creating a novel class of medicines to precisely target disease biology. Vilya aims to leverage its proprietary platform to focus on previously difficult-to-drug therapeutic targets. The platform, which is powered by machine learning, taps into uncharted chemical space to design molecular structures with ...
Covis Pharma | Pharmaceutical - The Pharmaletter
WEBCovis Pharma. A global pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. The Swiss company's primary products include Alvesco (ciclesonide), which was acquired in 2018 along with Omnaris and Zetonna, as well as Eklira (aclidinium bromide inhalation powder), known as ...
Synergy Pharmaceuticals | Biotechnology - The Pharmaletter
WEBUSA-based biopharma group Synergy Pharmaceuticals (Nasdaq: SGYP) is a biopharmaceutical company dedicated to developing new drugs to treat patients with gastrointestinal disorders and diseases. Based in New York, Synergy is led by a seasoned team of scientists, clinicians and executives with extensive experience in the biopharmaceutical industry.
Skip to content